

Gut–Brain Axis, Microbiome, and Neurodegenerative Diseases: Mechanistic Insights, Therapeutic Targets, and Translational Opportunities

DR. PREM KISHAN SINGHA

Assistant Professor, Department of Zoology, Rangia College, Assam. Email: singhapk2014@gmail.com
ORCID ID: 0009-0003-9975-5066
Submitted: April 15 2026; Accepted: May 20 2026; Publish: May 27 2026

Abstract: The gut–brain axis epitomizes a multifaceted bidirectional neuro-gastrointestinal communication paradigm, wherein the gastrointestinal tract and central nervous system engage through intricately orchestrated neural, endocrine, immunological, and metabolic conduits. A growing corpus of empirical evidence substantiates that perturbations in gut microbial architecture, commonly designated as dysbiosis, exhibit profound associations with both the initiation and trajectory of neurodegenerative pathologies, notably Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and multiple sclerosis. Metabolically active derivatives of the intestinal microbiota, encompassing short-chain fatty acids, bile acid conjugates, tryptophan catabolites, and a spectrum of neuroactive transmitters, are indispensable in the preservation of neural homeostasis, the modulation of neuroinflammatory cascades, and the regulation of protein misfolding dynamics that underpin these disorders. The advent of integrative meta-omics methodologies, spanning metagenomics, metatranscriptomics, metaproteomics, and metabolomics, has substantially deepened our mechanistic comprehension of host–microbiota reciprocity, concurrently unveiling prospective biomarkers of diagnostic relevance and putative molecular targets for therapeutic intervention. Innovative microbiome-modulatory strategies designed to reconstitute eubiotic equilibrium, including probiotics, prebiotics, fecal microbiota transplantation, precision dietary paradigms, and engineered microbial consortia, are currently under rigorous preclinical and early clinical scrutiny, yielding promising preliminary outcomes. This review endeavors to consolidate contemporary knowledge on the mechanistic substrata of the gut–brain axis in neurodegeneration, to synthesize disease-specific insights, and to critically appraise emerging therapeutic modalities, with a particular emphasis on translational feasibility and precision medicine applications.

Keywords: NA

1. Introduction

The human gastrointestinal tract harbors a prodigious consortium of microorganisms, collectively estimated at approximately 10¹⁴ cells, whose collective genomic reservoir exceeds that of the host by several orders of magnitude (Tilocca et al., 2020). This microbial ecosystem, which undergoes dynamic modulation throughout ontogeny, is sculpted by genetic predisposition, mode of parturition, early-life exposures, dietary regimens, aging, and diverse environmental contingencies (Sekirov et al., 2010). Under conditions of homeostasis, the intestinal microbiome orchestrates a multitude of indispensable physiological functions, ranging from nutrient catabolism and immunological maturation to neuroendocrine signaling. By contrast, deviations from this ecological balance, commonly denoted as dysbiosis, have been increasingly implicated in the etiopathogenesis of chronic human pathologies, most notably neurodegenerative disorders (Quigley, 2017; Sharon et al., 2016).



The gut–brain axis (GBA) epitomizes a highly intricate and reciprocal signaling network that integrates neural, endocrine, immune, and metabolic communication channels. This integrative system is principally mediated by the vagus nerve and enteric nervous system (ENS), the hypothalamic–pituitary–adrenal (HPA) axis, immune effector circuits, and microbiota-derived metabolites (Cryan et al., 2019). Within this framework, bioactive molecules such as short-chain fatty acids (SCFAs), bile acid derivatives, tryptophan catabolites, and microbiota-derived neurotransmitters (γ -aminobutyric acid, serotonin, dopamine) exert profound influences on glial activation, neuronal excitability, and synaptic plasticity (Sharon et al., 2016; Pellegrini et al., 2018).

Compelling experimental and translational evidence now indicates that perturbations in microbial communities compromise these signaling cascades, thereby fostering neuroinflammation, destabilizing the blood–brain barrier (BBB), and accelerating the misfolding and aggregation of pathogenic proteins such as amyloid- β , tau, and α -synuclein. In Parkinson’s disease, for example, Braak’s seminal hypothesis posits that aberrant α -synuclein aggregation may originate within the ENS and subsequently disseminate to the CNS via vagal conduits, while in Alzheimer’s disease dysregulated SCFA and bile acid profiles have been correlated with amyloidogenic and tauopathic processes (Tilocca et al., 2020). Moreover, diminished microbial diversity and metabolite deficiencies have been linked with progressive phenotypes in ALS and MS (Pellegrini et al., 2018).

The advent of high-throughput omics technologies has dramatically expanded our mechanistic appreciation of these phenomena. Metagenomics, metatranscriptomics, metaproteomics, and metabolomics provide complementary perspectives on microbial composition, gene expression, protein activity, and metabolic fluxes, thereby enabling a systems-level understanding of host–microbiome reciprocity. These integrative strategies have already revealed candidate biomarkers and therapeutic entry points with potential clinical utility (Tilocca et al., 2020).

2. Gut–Brain Axis: Communication Pathways

The GBA constitutes a multidimensional signaling matrix wherein gut-resident microbiota engage in continuous crosstalk with the CNS. This communication is executed via neural afferents and efferents, immune and inflammatory mediators, endocrine cascades, and microbiota-derived metabolites, all of which converge to regulate neuronal function and behavioral outcomes (Cryan et al., 2019; Tilocca et al., 2020).

2.1 Neural Pathways: Vagal and Enteric Signaling

The vagus nerve functions as the principal afferent conduit, relaying visceral sensory input to the brainstem and modulating limbic and hypothalamic networks. Experimental paradigms employing germ-free rodents underscore its indispensability, as microbial colonization reinstates vagal tone and restores normative behavioral phenotypes (Cryan et al., 2019). Parallel to this, the ENS—frequently characterized as the “second brain”—operates as a semi-autonomous neural network yet maintains bidirectional integration with the CNS. Importantly, microbial taxa such as *Lactobacillus* and *Bifidobacterium* produce neuroactive mediators, including γ -aminobutyric acid (GABA), dopamine, serotonin, and noradrenaline, which directly influence ENS excitability and gastrointestinal motility (Sharon et al., 2016). In mice, *Lactobacillus rhamnosus* JB-1 altered central GABA receptor expression and behavior through a vagus-dependent mechanism (Bravo et al., 2011). Microbial metabolites can also stimulate host enterochromaffin-cell serotonin biosynthesis; this should be distinguished from direct microbial serotonin production (Yano et al., 2015).

2.2 Immune Pathways: Microglial Priming and Neuroinflammation

The intestinal microbiota exerts profound influence on immune homeostasis, both locally and systemically. Dysbiosis perturbs gut-associated lymphoid tissue (GALT) function, resulting in dysregulated cytokine secretion (e.g., IL-1 β , IL-6, TNF- α), which either traverse the BBB or signal via vagal afferents to elicit central immune activation (Quigley, 2017). Microglia, the principal innate immune sentinels of the CNS, are exquisitely responsive to microbial signals. Under homeostatic conditions, SCFAs derived from commensal fermentation calibrate microglial maturation and functionality. By contrast, aberrant SCFA profiles engender chronic microglial activation, impair phagocytic clearance of protein aggregates, and potentiate synaptic pathology (Tilocca et al., 2020). Germ-free and antibiotic-

treated mice exhibit altered microglial maturation and responsiveness, with SCFAs contributing to the regulation of these phenotypes (Erny et al., 2015). Germ-free mice also show increased BBB permeability, which can be reduced by microbial colonization, providing experimental evidence for microbiota-dependent barrier regulation (Braniste et al., 2014).


2.3 Endocrine Pathways: HPA Axis and Stress Responsivity

The HPA axis integrates microbial cues into systemic neuroendocrine responses. Stress-evoked glucocorticoid secretion compromises intestinal barrier integrity, alters microbial diversity, and augments systemic inflammation. Conversely, microbial metabolites modulate HPA activity, influencing corticotropin-releasing hormone and cortisol secretion (Cryan et al., 2019). Furthermore, enteroendocrine cells (EECs), responsive to microbial signaling, release peptide hormones such as peptide YY (PYY), glucagon-like peptide-1 (GLP-1), and cholecystokinin (CCK), which exert pleiotropic effects on appetite regulation, metabolism, and CNS signaling (Sharon et al., 2016).

2.4 Metabolic Pathways: Neuromodulatory Metabolites

The metabolic repertoire of gut microbiota includes a wide spectrum of neuroactive compounds:

- **SCFAs (butyrate, acetate, propionate):** fortify BBB integrity, regulate gene transcription via histone deacetylase inhibition, and orchestrate microglial differentiation. However, excessive SCFA exposure in experimental paradigms has paradoxically exacerbated amyloid and α -synuclein pathologies (Tilocca et al., 2020).
- **Tryptophan metabolism:** generates both neuroprotective indole derivatives (via aryl hydrocarbon receptor signaling) and neurotoxic kynurenine metabolites such as quinolinic acid (Sharon et al., 2016).
- **Bile acids:** microbial conversion of primary into secondary bile acids alters signaling via FXR and TGR5, with dysregulated bile acid pools linked to cognitive decline and Parkinsonian pathology (Quigley, 2017).
- **Polyphenol catabolites:** microbial transformation of dietary polyphenols yields antioxidative and anti-inflammatory derivatives, thereby modulating neuronal survival (Pellegrini et al., 2018).



2.5 Mitochondrial Dysfunction and Oxidative Stress

Microbiota–host interactions extend into mitochondrial physiology. Dysbiosis exacerbates reactive oxygen species (ROS) generation, induces mitochondrial DNA lesions, and disrupts ATP synthesis, thereby contributing to neuronal demise (Tilocca et al., 2020). Notably, specific microbial metabolites regulate mitochondrial redox balance, underscoring a mechanistic nexus between intestinal dysbiosis, oxidative stress, and neurodegeneration.

2.6 Protein Misfolding and Amyloidogenesis

Bacterial amyloids, such as those produced by *Escherichia coli*, may act as molecular mimetics capable of cross-seeding host proteins including amyloid- β , tau, and α -synuclein. This phenomenon may potentiate amyloidogenic cascades implicated in Alzheimer's and Parkinson's disease. Consistent with Braak's hypothesis, experimental evidence suggests that misfolded α -synuclein pathology can emerge within the gut and ascend to the CNS via vagal conduits (Cryan et al., 2019; Sharon et al., 2016). More specifically, colonization with curli-producing *Escherichia coli* enhanced α -synuclein aggregation and motor impairment in susceptible mice, providing evidence for a bacterial amyloid contribution to synucleinopathy (Sampson et al., 2020).


3. Microbiome Dysbiosis in Major Neurodegenerative Diseases

An expanding body of translational and clinical research substantiates the hypothesis that gut microbial dysbiosis is not a mere epiphenomenon but a significant pathophysiological determinant across multiple neurodegenerative conditions. Although each disease is defined by unique molecular and clinical hallmarks, convergent alterations in microbial ecology and metabolite fluxes suggest a unifying role for the GBA (Tilocca et al., 2020).

3.1 Alzheimer's Disease (AD)

Alzheimer's disease, the predominant cause of dementia globally, is characterized by extracellular deposition of amyloid- β (A β), intracellular neurofibrillary tangles of hyperphosphorylated tau, and progressive synaptic attrition. Increasingly, perturbations in gut microbiota have been implicated in disease onset and progression.

- **Microbial composition:** Multiple cohorts report reductions in butyrate-producing commensals such as *Faecalibacterium* and *Eubacterium*, coupled with overrepresentation of pro-inflammatory taxa including *Escherichia/Shigella* (Sharon et al., 2016). A human case-control study identified reduced microbial diversity and altered bacterial composition in AD, although its observational design does not establish causation (Vogt et al., 2017).
- **Metabolite disruption:** Deficient SCFA pools compromise microglial phagocytic clearance of A β and amplify neuroinflammation. Conversely, experimental excess of SCFAs has been shown to exacerbate plaque burden, underscoring their dual, context-dependent role (Tilocca et al., 2020). Germ-free APPPS1 mice showed reduced cerebral amyloid pathology, supporting a microbial contribution in this experimental model (Harach et al., 2017). SCFA supplementation promoted microglial alterations and A β plaque deposition in APPPS1 mice, demonstrating that metabolite effects depend on the disease model and exposure conditions (Colombo et al., 2021).
- **Cross-seeding phenomena:** Bacterial amyloids and lipopolysaccharides (LPS) have been demonstrated to potentiate A β aggregation, thereby accelerating pathogenic cascades (Quigley, 2017).
- **Therapeutic insights:** Probiotic interventions, including *Clostridium butyricum*, have demonstrated restoration of SCFA levels, attenuation of gliosis, and amelioration of cognitive decline in murine models (Pellegrini et al., 2018).



3.2 Parkinson's Disease (PD)

Parkinson's disease is typified by degeneration of dopaminergic neurons in the substantia nigra pars compacta and pathogenic α -synuclein aggregation. Gastrointestinal dysfunction frequently precedes motor manifestations, suggesting a gut-centric initiation.

- **Microbial dysbiosis:** PD patients consistently exhibit depletion of *Prevotella* and enrichment of *Enterobacteriaceae*, taxa associated with intestinal permeability and endotoxemia (Tilocca et al., 2020). Scheperjans et al. (2015) reported reduced Prevotellaceae abundance and an association between Enterobacteriaceae abundance and motor phenotype; these cohort-specific findings require validation across populations.

- **Propagation hypothesis:** Braak's model posits that α -synuclein pathology originates within the ENS and ascends to the CNS through vagal pathways. Both rodent models and human data lend credence to this hypothesis (Cryan et al., 2019).
- **Metabolic dimensions:** SCFAs exert bidirectional effects: physiological levels support neuroprotection and glial homeostasis, whereas pathological elevations potentiate α -synuclein aggregation and microgliosis (Sharon et al., 2016). In α -synuclein-overexpressing mice, microbial colonization and SCFA administration promoted neuroinflammation and motor deficits, whereas microbiota depletion attenuated these outcomes (Sampson et al., 2016).
- **Bile acid alterations:** Reduced concentrations of neuroprotective bile acids such as ursodeoxycholic acid (UDCA) have been correlated with nigrostriatal degeneration (Quigley, 2017).

3.3 Amyotrophic Lateral Sclerosis (ALS)

ALS is a relentlessly progressive neurodegenerative disease defined by the degeneration of upper and lower motor neurons, frequently associated with TDP-43 proteinopathy. Emerging evidence implicates gut microbial perturbations in modulating disease trajectory.

- **Microbial alterations:** Clinical and preclinical studies have revealed depletion of *Akkermansia muciniphila* and other SCFA-producing taxa (Tilocca et al., 2020).
- **Metabolic correlates:** Dysbiosis-induced nicotinamide deficiency has been implicated in impaired mitochondrial energetics and hastened neurodegeneration (Sharon et al., 2016). Blacher et al. (2019) identified microbiome-dependent modulation of disease severity in SOD1-transgenic mice and implicated *Akkermansia*-associated nicotinamide availability; these findings remain primarily preclinical.
- **Therapeutic prospects:** Supplementation with *A. muciniphila* or butyrate restored intestinal integrity, dampened neuroinflammation, and prolonged survival in ALS murine models (Pellegrini et al., 2018).

3.4 Multiple Sclerosis (MS)

MS is a chronic autoimmune demyelinating disorder, wherein aberrant gut-immune communication is increasingly recognized as pathogenic.

- **Microbial dysbiosis:** Reduced abundance of *Clostridia* clusters and *Bacteroides fragilis*, taxa associated with regulatory T cell induction, have been consistently observed in MS (Tilocca et al., 2020).
- **Immune imbalance:** SCFA deficiencies hinder Treg differentiation, fostering pro-inflammatory Th1/Th17 polarization and exacerbating CNS demyelination (Sharon et al., 2016). Patient-derived bacterial isolates altered human T-cell responses, and transplantation of MS-associated microbiota exacerbated disease in experimental autoimmune encephalomyelitis models (Cekanaviciute et al., 2017).
- **Preclinical validation:** The effects of microbial depletion and recolonization on demyelinating pathology depend on the experimental model and the microbial community involved (Cryan et al., 2019). However, microbial effects are model-dependent: microbiota from affected members of MS-discordant twin pairs promoted spontaneous autoimmune encephalomyelitis in susceptible recipient mice (Berer et al., 2017).


3.5 Huntington's Disease (HD)

Huntington's disease, a monogenic trinucleotide repeat disorder, culminates in toxic huntingtin protein aggregation and neurodegeneration. Though less extensively characterized, microbial involvement has been increasingly documented.

- **Microbial community shifts:** Both clinical and animal data report depletion of Firmicutes with concomitant expansion of Bacteroidetes, correlating with motor and cognitive deficits (Tilocca et al., 2020).

A human study of Huntington’s disease gene expansion carriers found altered microbial community composition and reduced alpha diversity, with associations involving cognitive and clinical measures (Wasser et al., 2020). These associations do not establish that dysbiosis initiates HD.

- **Barrier dysfunction:** Intestinal hyperpermeability in HD models has been implicated in systemic inflammation and neurotoxicity (Sharon et al., 2016).
- **Therapeutic implications:** Early investigations into fecal microbiota transplantation and dietary modulation suggest partial restitution of microbial diversity and behavioral improvements (Pellegrini et al., 2018).



3.6 Comparative Insights

Despite nosological differences, convergent microbiome-related patterns are evident across neurodegenerative conditions:

- Consistent depletion of SCFA-producing commensals.
- Expansion of pathobionts and pro-inflammatory taxa.
- Perturbations in tryptophan and bile acid metabolic pathways.
- Dualistic effects of microbial metabolites, wherein protective or deleterious outcomes are context-dependent.

4. Therapeutic Applications and Clinical Evidence

The elucidation of the microbiota–GBA as a pivotal modulator of neurodegeneration has catalyzed the pursuit of microbiome-targeted interventions. These therapeutic modalities are conceived to re-establish eubiotic equilibrium, recalibrate metabolite production, and attenuate neuropathological cascades (Tilocca et al., 2020; Sharon et al., 2016).

4.1 Probiotics, Prebiotics, and Synbiotics

Probiotic, prebiotic, and synbiotic interventions constitute cardinal strategies for recalibrating the gut microbiome with potential ramifications in neurodegenerative pathobiology. **Probiotics**, notably strains belonging to *Lactobacillus* and *Bifidobacterium*, have been documented to remodel microbial consortia, replenish depleted pools of short-chain fatty acids (SCFAs), and ameliorate cognitive dysfunction in experimental models of Alzheimer's and Parkinson's disease (Pellegrini et al., 2018). From a translational vantage, preliminary clinical investigations further corroborate these outcomes, revealing that probiotic supplementation augments Mini-Mental State Examination (MMSE) performance while simultaneously mitigating oxidative stress biomarkers in AD cohorts (Sharon et al., 2016). **Prebiotics**, exemplified by indigestible carbohydrates such as inulin and galactooligosaccharides, selectively potentiate the expansion of SCFA-generating commensals, thereby fortifying intestinal barrier architecture and sustaining systemic immunological equilibrium (Quigley, 2017). Furthermore, **synbiotics**, which strategically integrate probiotic taxa with prebiotic substrates, elicit synergistic effects through concurrent ecological modulation and metabolite amplification, thereby promoting metabolic homeostasis and attenuating pro-inflammatory cascades, although rigorous clinical substantiation is still at a nascent stage (Tilocca et al., 2020). In a 12-week randomized trial involving 60 patients with AD, probiotic milk was associated with improved MMSE scores and changes in selected metabolic markers; the limited sample and follow-up constrain conclusions about disease modification (Akbari et al., 2016).

4.2 Fecal Microbiota Transplantation (FMT)

FMT seeks to reconstitute intestinal microbial diversity through the engraftment of a donor microbiome.

Preclinical investigations in murine paradigms of Alzheimer's and Parkinson's disease have revealed that fecal microbiota transplantation (FMT) confers salutary effects, including augmentation of memory retention, enhancement of motor coordination, and attenuation of glial hyperactivation (Tilocca et al., 2020). Complementing these experimental insights, limited case series and preliminary clinical trials in human cohorts have reported analogous benefits, with FMT contributing to measurable improvements in both cognitive and motor domains in patients with AD and PD (Sharon et al., 2016). Notwithstanding these encouraging outcomes, formidable constraints persist, encompassing inter-donor heterogeneity in microbial consortia, the potential hazard of transmissible pathogens, and the current paucity of harmonized regulatory frameworks governing therapeutic implementation, all of which collectively impede large-scale clinical translation. The safety concern is supported by documented transmission of drug-resistant *Escherichia coli* bacteremia through FMT in immunocompromised recipients, emphasizing the need for rigorous donor screening (DeFilipp et al., 2019).

4.3 Dietary Interventions

Dietary composition exerts profound and rapid effects on microbial ecology, rendering nutrition a modifiable therapeutic axis. Short-term animal-based and plant-based dietary interventions rapidly altered human gut microbial composition and activity, supporting diet as a practical microbiome-modifying strategy (David et al., 2014).

Dietary interventions represent a pivotal modulatory axis for reshaping host–microbiome interactions and influencing neurodegenerative trajectories. The **Mediterranean diet**, characterized by an abundance of polyphenols, fermentable fibers, and omega-3 fatty acids, is consistently correlated with enhanced microbial diversity, amplified short-chain fatty acid (SCFA) biosynthesis, and a mitigated risk of cognitive decline (Pellegrini et al., 2018). By contrast, the **ketogenic diet** reconfigures gut microbial consortia, augments systemic ketone body concentrations, and reinforces mitochondrial bioenergetics, with preclinical paradigms in Alzheimer's and Parkinson's disease substantiating its neuroprotective efficacy (Sharon et al., 2016). Additionally, **polyphenol-rich dietary regimens**, through microbial catabolism of flavonoids and phenolic derivatives, generate bioactive metabolites endowed with antioxidative and anti-inflammatory properties, thereby conferring direct neuroprotection against pathogenic processes underlying neurodegeneration (Quigley, 2017). In the NU-AGE study, a one-year Mediterranean dietary intervention in older adults was associated with microbiome changes linked to lower frailty and improved health-related measures; it did not demonstrate prevention of neurodegenerative disease (Ghosh et al., 2020).

4.4 Postbiotics and Engineered Microbes

Microbial metabolite-based interventions include molecules such as butyrate and indole-3-propionic acid (IPA), which have been investigated for effects on mitochondrial function and oxidative stress in experimental settings. Experimental investigations demonstrate that exogenous butyrate supplementation not only prolongs survival but also reinstates intestinal integrity in amyotrophic lateral sclerosis (ALS) models, underscoring its translational promise (Tilocca et al., 2020). In parallel, engineered probiotics, enabled by advances Terminology requires precision: the ISAPP consensus defines postbiotics as preparations of inanimate microorganisms and/or their components that confer a host health benefit; purified microbial metabolites alone do not meet this definition (Salminen et al., 2021). In synthetic biology, have been tailored to secrete neuroactive metabolites, including γ -aminobutyric acid (GABA), dopamine analogues, and immunomodulatory peptides, thus representing a vanguard of precision microbiome therapeutics designed to recalibrate host–microbiota–CNS communication (Sharon et al., 2016).

4.5 Nanotechnology and Artificial Intelligence (AI)

Nanotechnology-based strategies have emerged as transformative tools to augment the therapeutic potential of microbiome-directed interventions, wherein encapsulation platforms enhance the stability, bioavailability, and site-specific delivery of probiotics and microbial metabolites. Illustratively, nanoparticle-mediated administration of tauroursodeoxycholic acid (TUDCA) has demonstrated marked neuroprotective efficacy in experimental models of Parkinson's disease, thereby exemplifying the translational utility of nanoscale delivery systems (Sharon et al., 2016). In parallel, **artificial intelligence–driven methodologies**, particularly the deployment of machine learning algorithms integrated with multi-omics datasets, are enabling sophisticated predictive frameworks capable of modeling disease trajectories, delineating microbial biomarkers, and forecasting individualized therapeutic responsiveness. Such computational infrastructures are poised to constitute the foundational architecture of precision microbiome medicine, bridging discovery science with clinically actionable interventions (Tilocca et al., 2020).

4.6 Clinical Trials and Translational Advances

Clinical investigations underscore the translational potential of microbiome-targeted therapies:

Within the clinical domain, microbiome-targeted interventions have already yielded encouraging disease-specific outcomes. In **Alzheimer's disease (AD)**, administration of probiotic consortia has been associated with enhanced cognitive performance and concomitant reductions in systemic oxidative stress, underscoring the therapeutic promise of microbial modulation (Sharon et al., 2016). In **Parkinson's disease (PD)**, ongoing clinical investigations are assessing the efficacy of ursodeoxycholic acid (UDCA) and dietary prebiotic supplementation as modulators of mitochondrial bioenergetics and intestinal barrier integrity, reflecting the expanding translational horizon of microbiome-directed therapeutics (Tilocca et al., 2020). Likewise, in **multiple sclerosis (MS)**, probiotic interventions have demonstrated the capacity to attenuate inflammatory signatures while reducing Expanded Disability Status Scale (EDSS) scores, thereby reinforcing the role of microbial modulation in reshaping neuroinflammatory cascades (Quigley, 2017). In a small MS intervention study, a multispecies probiotic altered microbial composition and peripheral immune profiles, supporting biological activity rather than establishing a sustained reduction in disability (Tankou et al., 2018).

5. Challenges and Limitations

Despite the burgeoning evidence implicating the microbiota–GBA in the etiopathogenesis of neurodegenerative disorders, formidable challenges impede its seamless translation into therapeutic paradigms. These constraints span the experimental, clinical, methodological, and regulatory spectra, necessitating rigorous refinement before microbiome-based interventions can be integrated into mainstream neurology.

5.1 Translational Disparities between Animal Models and Human Disease

Mechanistic insights into the GBA have been predominantly derived from germ-free animals, antibiotic-depleted rodents, and transgenic disease models. Although invaluable for delineating causal links, these models cannot fully recapitulate the intricacies of human microbiota composition, dietary influences, or neurodegenerative trajectories. Consequently, extrapolation from preclinical paradigms to clinical outcomes remains tenuous (Tilocca et al., 2020).

5.2 Inter-Individual Microbiome Variability

Human gut microbiota display profound inter-individual heterogeneity shaped by host genetics, geographical locale, cultural dietary practices, aging, and environmental exposures. This variability complicates the identification of universally conserved microbial biomarkers across neurodegenerative diseases (Quigley, 2017). Furthermore, microbial dysbiosis signatures reported in one population often lack reproducibility across cohorts, underscoring the necessity for personalized and context-specific therapeutic frameworks (Sharon et al., 2016).

5.3 Context-Dependent Duality of Microbial Metabolites

Microbial metabolites are not uniformly beneficial; their effects are profoundly context-dependent. For example, SCFAs typically promote neuroprotection by maintaining BBB integrity and modulating microglial maturation. Yet, paradoxically, supraphysiological SCFA levels have been shown to exacerbate amyloidogenic cascades in Alzheimer's disease and potentiate α -synuclein aggregation in Parkinson's disease (Tilocca et al., 2020). Likewise, tryptophan metabolism bifurcates into neuroprotective indole derivatives and neurotoxic kynurenine metabolites such as quinolinic acid (Sharon et al., 2016). This biochemical duality complicates therapeutic exploitation.

5.4 Constraints in Clinical Trial Design

Existing clinical studies examining probiotics, prebiotics, or fecal microbiota transplantation (FMT) are generally constrained by small sample sizes, short follow-up durations, and restricted geographic representation. Such limitations preclude robust generalization of findings and impede the assessment of long-term efficacy and safety. Moreover, FMT protocols remain inconsistent across trials, with no consensus regarding donor screening, preparation, or administration (Quigley, 2017).

5.5 Methodological and Technical Hurdles

While meta-omics platforms have revolutionized microbiome research, each technique is inherently constrained.

High-throughput **meta-omics platforms** have substantially expanded the investigative repertoire of microbiome research, yet each modality remains intrinsically constrained. **Metagenomics** enables exhaustive cataloguing of microbial gene content but fails to capture the transcriptional dynamics underlying functional activity. By contrast, **metatranscriptomic and metaproteomic approaches** furnish insights into community-level expression states and protein activity, though their interpretive power is frequently undermined by incomplete reference databases and significant analytical complexity. Finally, **metabolomics** provides a direct window into biochemical outputs and metabolic fluxes; however, metabolite origin cannot be consistently assigned to specific microbial taxa, thereby limiting its taxonomic resolution (Tilocca et al., 2020).

The integration of these datasets into coherent multi-omics frameworks requires advanced bioinformatics infrastructure, yet cross-platform standardization remains inadequate, thereby hindering reproducibility and translational applicability.

5.6 Regulatory and Ethical Considerations

Therapeutic modalities such as FMT and engineered microbial consortia evoke regulatory and ethical concerns. Potential risks include pathogen transmission, unintended immune perturbations, and unpredictable ecological impacts

on host microbiota. Current regulatory frameworks remain fragmented, with substantial gaps in safety assessment, standardization, and long-term monitoring of microbiome-based therapeutics (Sharon et al., 2016).

Figure 8 (Flowchart suggestion): A schematic depiction of the multifaceted barriers to translation, encompassing experimental limitations, inter-individual variability, metabolite duality, clinical trial inadequacies, technical hurdles, and regulatory uncertainties.

6. Future Perspectives

The microbiota–GBA has emerged as a transformative paradigm in neurology, yet its full clinical realization will depend on bridging mechanistic insights with translational innovations. Future investigations must integrate **multi-omics technologies, artificial intelligence (AI)–driven analytics, and precision therapeutics** to convert correlative associations into actionable interventions (Tilocca et al., 2020).

6.1 Multi-Omics Convergence for Systems-Level Precision Medicine

Single-omics approaches, while illuminating, offer only fragmentary depictions of host–microbiome reciprocity. The integration of metagenomics, metatranscriptomics, metaproteomics, and metabolomics promises a comprehensive systems-level framework capable of delineating microbial functionality, metabolic fluxes, and disease-specific perturbations. Such holistic analyses are poised to yield **robust biomarkers of diagnostic utility and novel therapeutic targets**, enabling stratification of neurodegenerative subtypes on the basis of microbiome signatures (Tilocca et al., 2020).

6.2 Artificial Intelligence and Predictive Analytics

The complexity and dimensionality of microbiome datasets necessitate advanced computational methodologies. AI and machine learning platforms are increasingly capable of disentangling these data, predicting disease trajectories, and modeling patient-specific therapeutic responses. By integrating multi-omics profiles with clinical phenotypes, predictive algorithms may refine early diagnosis, personalize dietary or probiotic interventions, and optimize therapeutic regimens in neurodegeneration (Sharon et al., 2016).

6.3 Next-Generation Therapeutic Modalities

Traditional probiotic and prebiotic interventions are increasingly being eclipsed by **next-generation microbiome therapeutics** that offer greater mechanistic precision and translational potential. Among these, **engineered probiotics**, microbial chassis genetically tailored to secrete neuroactive compounds such as γ -aminobutyric acid (GABA), dopamine analogues, or immunomodulatory peptides, are emerging as a vanguard frontier in host–microbiota modulation (Sharon et al., 2016). In parallel, **postbiotic strategies**, which involve the direct administration of defined microbial metabolites including butyrate, indole-3-propionic acid, and bile acid derivatives, circumvent the inter-individual variability and ecological unpredictability inherent to live microbial interventions, thereby affording a more consistent and controllable pharmacodynamic profile. Additionally, **designer microbial consortia**, rationally constructed from selected taxa, are being explored to elicit targeted neuroprotective and anti-inflammatory effects, with potential customization to discrete disease phenotypes, thereby advancing the paradigm of precision microbiome medicine.

6.4 Nanotechnology and Targeted Delivery Systems

Nanotechnology offers unprecedented precision in stabilizing and delivering microbiome-based therapeutics. Nanocarriers can protect probiotics from gastric degradation, ensure colon-specific release, and facilitate brain-directed metabolite delivery. For example, tauroursodeoxycholic acid (TUDCA) nanoparticles have demonstrated neuroprotective efficacy in experimental models of Parkinson's disease (Pellegrini et al., 2018).

6.5 Early-Life Interventions and Preventive Strategies

Given that microbiota colonization commences at birth and exerts durable influences on immunological and neurological development, **perinatal and early-life interventions** may significantly modulate long-term susceptibility to neurodegeneration. Maternal nutritional optimization, judicious antibiotic stewardship, and neonatal probiotic supplementation represent promising preventive avenues (Quigley, 2017). Such strategies may ultimately reduce disease incidence rather than merely delaying progression.

6.6 Toward Clinical Translation

The clinical mainstreaming of microbiome therapeutics in neurodegeneration will require:

- **Standardized methodologies** for microbiome profiling and biomarker validation.
- **Longitudinal, multi-center cohorts** spanning diverse populations to capture ecological and genetic variability.
- **Rigorous randomized controlled trials (RCTs)** with long-term follow-up to establish safety, durability, and reproducibility of interventions.
- **Regulatory harmonization** to ensure standardized quality control of probiotics, postbiotics, and fecal microbiota transplantation (FMT) products (Tilocca et al., 2020).

7. Conclusion

The microbiota–gut–brain axis (GBA) has transitioned from a conceptual framework to a mechanistic paradigm that fundamentally redefines our understanding of neurodegenerative pathophysiology. A convergence of experimental and clinical evidence demonstrates that perturbations in microbial community structure and function are intricately linked with Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and multiple sclerosis. Through bioactive mediators—including short-chain fatty acids, bile acid derivatives, tryptophan metabolites, and microbiota-derived neurotransmitters—dysbiosis modulates neuroinflammatory cascades, mitochondrial integrity, and proteostatic balance, thereby accelerating neurodegenerative trajectories (Tilocca et al., 2020; Sharon et al., 2016).

Notwithstanding these advances, translational hurdles persist. Inter-individual variability, the bidirectional and context-dependent nature of microbial metabolites, and the paucity of standardized long-term clinical trials remain formidable obstacles (Quigley, 2017). Yet, the integration of **multi-omics technologies, artificial intelligence–driven predictive analytics, nanotechnology-enabled delivery systems, and next-generation microbial therapeutics** offers unprecedented opportunities to transform these insights into clinically actionable strategies (Pellegrini et al., 2018).

The imperative for the coming decade will be to evolve beyond correlation toward causation, deploying robust longitudinal cohorts and randomized controlled trials to validate therapeutic efficacy and safety. If these challenges are met, microbiome-based interventions could transcend symptomatic management and inaugurate a new era of precision neurology—one in which modulation of the gut microbiome is leveraged not merely to mitigate disease burden but potentially to delay, or even prevent, the inexorable progression of neurodegeneration.

REFERENCES

1. Tilocca, B., Pieroni, L., Soggiu, A., Britti, D., Bonizzi, L., Roncada, P., & Greco, V. (2020). Gut–brain axis and neurodegeneration: state-of-the-art of meta-omics sciences for microbiota characterization. *International journal of molecular sciences*, 21(11), 4045. <https://doi.org/10.3390/ijms21114045>
2. Sekirov, I., Russell, S. L., Antunes, L. C. M., & Finlay, B. B. (2010). Gut microbiota in health and disease. *Physiological reviews*. <https://doi.org/10.1152/physrev.00045.2009>
3. Quigley, E.M.M. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. *Curr Neurol Neurosci Rep* 17, 94 (2017). <https://doi.org/10.1007/s11910-017-0802-6>
4. Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016). The central nervous system and the gut microbiome. *Cell*, 167(4), 915-932. <http://dx.doi.org/10.1016/j.cell.2016.10.027>

5. Pellegrini, C., Antonioli, L., Colucci, R. et al. Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?. *Acta Neuropathol* 136, 345–361 (2018). <https://doi.org/10.1007/s00401-018-1856-5>
6. Cryan, J. F., O’Riordan, K. J., Cowan, C. S., Sandhu, K. V., Bastiaanssen, T. F., Boehme, M., ... & Dinan, T. G. (2019). The microbiota-gut-brain axis. *Physiological reviews*. <https://doi.org/10.1152/physrev.00018.2018>
7. Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., Korecka, A., Bakocevic, N., Ng, L. G., Kundu, P., Gulyás, B., Halldin, C., Hultenby, K., Nilsson, H., Hebert, H., Volpe, B. T., Diamond, B., & Pettersson, S. (2014). The gut microbiota influences blood-brain barrier permeability in mice. *Science Translational Medicine*, 6(263), 263ra158. <https://doi.org/10.1126/scitranslmed.3009759>
8. Erny, D., Hrabě de Angelis, A. L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., Keren-Shaul, H., Mhlahoi, T., Jakobshagen, K., Buch, T., Schwierzeck, V., Utermöhlen, O., Chun, E., Garrett, W. S., McCoy, K. D., Diefenbach, A., Staeheli, P., Stecher, B., Amit, I., & Prinz, M. (2015). Host microbiota constantly control maturation and function of microglia in the CNS. *Nature Neuroscience*, 18(7), 965–977. <https://doi.org/10.1038/nn.4030>
9. Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., Dinan, T. G., Bienenstock, J., & Cryan, J. F. (2011). Ingestion of *Lactobacillus* strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. *Proceedings of the National Academy of Sciences*, 108(38), 16050–16055. <https://doi.org/10.1073/pnas.1102999108>
10. Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015). Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis. *Cell*, 161(2), 264–276. <https://doi.org/10.1016/j.cell.2015.02.047>
11. Vogt, N. M., Kerby, R. L., Dill-McFarland, K. A., Harding, S. J., Merluzzi, A. P., Johnson, S. C., Carlsson, C. M., Asthana, S., Zetterberg, H., Blennow, K., Bendlin, B. B., & Rey, F. E. (2017). Gut microbiome alterations in Alzheimer’s disease. *Scientific Reports*, 7(1), 13537. <https://doi.org/10.1038/s41598-017-13601-y>
12. Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., Neher, J. J., Fåk, F., Jucker, M., Lasser, T., & Bolmont, T. (2017). Reduction of Aβ amyloid pathology in APPS1 transgenic mice in the absence of gut microbiota. *Scientific Reports*, 7(1), 41802. <https://doi.org/10.1038/srep41802>
13. Colombo, A. V., Sadler, R. K., Llovera, G., Singh, V., Roth, S., Heindl, S., Sebastian Monasor, L., Verhoeven, A., Peters, F., Parhizkar, S., Kamp, F., Gomez de Agüero, M., MacPherson, A. J., Winkler, E., Herms, J., Benakis, C., Dichgans, M., Steiner, H., Giera, M., ..., & Liesz, A. (2021). Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition. *eLife*, 10, e59826. <https://doi.org/10.7554/elife.59826>
14. Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., Chesselet, M. F., Keshavarzian, A., Shannon, K. M., Krajmalnik-Brown, R., Wittung-Stafshede, P., Knight, R., & Mazmanian, S. K. (2016). Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease. *Cell*, 167(6), 1469–1480.e12. <https://doi.org/10.1016/j.cell.2016.11.018>
15. Sampson, T. R., Challis, C., Jain, N., Moiseyenko, A., Ladinsky, M. S., Shastri, G. G., Thron, T., Needham, B. D., Horvath, I., Debelius, J. W., Janssen, S., Knight, R., Wittung-Stafshede, P., Gradinaru, V., Chapman, M., & Mazmanian, S. K. (2020). A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice. *eLife*, 9, e53111. <https://doi.org/10.7554/elife.53111>
16. Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola-Rautio, J., Pohja, M., Kinnunen, E., Murros, K., & Auvinen, P. (2015). Gut microbiota are related to Parkinson’s disease and clinical phenotype. *Movement Disorders*, 30(3), 350–358. <https://doi.org/10.1002/mds.26069>
17. Blacher, E., Bashirades, S., Shapiro, H., Rothschild, D., Mor, U., Dori-Bachash, M., Kleimyer, C., Moresi, C., Harnik, Y., Zur, M., Zabari, M., Brik, R. B. Z., Kviatkovsky, D., Zmora, N., Cohen, Y., Bar, N., Levi, I., Amar, N., Mehlman, T., ..., & Elinav, E. (2019). Potential roles of gut microbiome and metabolites in modulating ALS in mice. *Nature*, 572(7770), 474–480. <https://doi.org/10.1038/s41586-019-1443-5>
18. Cekanaviciute, E., Yoo, B. B., Runia, T. F., Debelius, J. W., Singh, S., Nelson, C. A., Kanner, R., Bencosme, Y., Lee, Y. K., Hauser, S. L., Crabtree-Hartman, E., Sand, I. K., Gacias, M., Zhu, Y., Casaccia, P., Cree, B. A. C., Knight, R., Mazmanian, S. K., & Baranzini, S. E. (2017). Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. *Proceedings of the National Academy of Sciences*, 114(40), 10713–10718. <https://doi.org/10.1073/pnas.1711235114>
19. Berer, K., Gerdes, L. A., Cekanaviciute, E., Jia, X., Xiao, L., Xia, Z., Liu, C., Klotz, L., Stauffer, U., Baranzini, S. E., Kümpfel, T., Hohlfeld, R., Krishnamoorthy, G., & Wekerle, H. (2017). Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. *Proceedings of the National Academy of Sciences*, 114(40), 10719–10724. <https://doi.org/10.1073/pnas.1711233114>
20. Tankou, S. K., Regev, K., Healy, B. C., Tjon, E., Laghi, L., Cox, L. M., Kivisäkk, P., Pierre, I. V., Hrishikesh, L., Gandhi, R., Cook, S., Glanz, B., Stankiewicz, J., & Weiner, H. L. (2018). A probiotic modulates the microbiome and immunity in multiple sclerosis. *Annals of Neurology*, 83(6), 1147–1161. <https://doi.org/10.1002/ana.25244>
21. Wasser, C. I., Mercieca, E. C., Kong, G., Hannan, A. J., McKeown, S. J., Glikmann-Johnston, Y., & Stout, J. C. (2020). Gut dysbiosis in Huntington’s disease: associations among gut microbiota, cognitive performance and clinical outcomes. *Brain Communications*, 2(2), fcaa110. <https://doi.org/10.1093/braincomms/fcaa110>

22. David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., Biddinger, S. B., Dutton, R. J., & Turnbaugh, P. J. (2014). Diet rapidly and reproducibly alters the human gut microbiome. *Nature*, 505(7484), 559-563. <https://doi.org/10.1038/nature12820>
23. Ghosh, T. S., Rampelli, S., Jeffery, I. B., Santoro, A., Neto, M., Capri, M., Giampieri, E., Jennings, A., Candela, M., Turrioni, S., Zoetendal, E. G., Hermes, G. D. A., Elodie, C., Meunier, N., Brugere, C. M., Pujos-Guillot, E., Berendsen, A. M., De Groot, L. C. P. G. M., Feskens, E. J. M., ..., & O'Toole, P. W. (2020). Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. *Gut*, 69(7), 1218-1228. <https://doi.org/10.1136/gutjnl-2019-319654>
24. Salminen, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., Sanders, M. E., Shamir, R., Swann, J. R., Szajewska, H., & Vinderola, G. (2021). The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. *Nature Reviews Gastroenterology & Hepatology*, 18(9), 649-667. <https://doi.org/10.1038/s41575-021-00440-6>
25. DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R., Huntley, M. H., Turbett, S., Chung, R. T., Chen, Y. B., & Hohmann, E. L. (2019). Drug-Resistant *E. coli* Bacteremia Transmitted by Fecal Microbiota Transplant. *New England Journal of Medicine*, 381(21), 2043-2050. <https://doi.org/10.1056/nejmoa1910437>
26. Akbari, E., Asemi, Z., Daneshvar Kakhaki, R., Bahmani, F., Kouchaki, E., Tamtaji, O. R., Hamidi, G. A., & Salami, M. (2016). Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial. *Frontiers in Aging Neuroscience*, 8, 256. <https://doi.org/10.3389/fnagi.2016.00256>